Open Access Highly Accessed Open Badges Research

An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report

Barbara C Olendzki1*, Taryn D Silverstein2, Gioia M Persuitte1, Yunsheng Ma1, Katherine R Baldwin3 and David Cave2

Author Affiliations

1 Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School, 55 Lake Ave North, Shaw Building, Worcester MA, USA

2 Department of Gastroenterology, (UMass) Memorial Medical Center, 55 Lake Ave North, Worcester MA, USA

3 Department of Medicine and Pediatrics, UMass Memorial Medical Center, Worcester MA, USA

For all author emails, please log on.

Nutrition Journal 2014, 13:5  doi:10.1186/1475-2891-13-5

Published: 16 January 2014



The Anti-Inflammatory Diet (IBD-AID) is a nutritional regimen for inflammatory bowel disease (IBD) that restricts the intake of certain carbohydrates, includes the ingestion of pre- and probiotic foods, and modifies dietary fatty acids to demonstrate the potential of an adjunct dietary therapy for the treatment of IBD.


Forty patients with IBD were consecutively offered the IBD-AID to help treat their disease, and were retrospectively reviewed. Medical records of 11 of those patients underwent further review to determine changes in the Harvey Bradshaw Index (HBI) or Modified Truelove and Witts Severity Index (MTLWSI), before and after the diet.


Of the 40 patients with IBD, 13 patients chose not to attempt the diet (33%). Twenty-four patients had either a good or very good response after reaching compliance (60%), and 3 patients’ results were mixed (7%). Of those 11 adult patients who underwent further medical record review, 8 with CD, and 3 with UC, the age range was 19–70 years, and they followed the diet for 4 or more weeks. After following the IBD-AID, all (100%) patients were able to discontinue at least one of their prior IBD medications, and all patients had symptom reduction including bowel frequency. The mean baseline HBI was 11 (range 1–20), and the mean follow-up score was 1.5 (range 0–3). The mean baseline MTLWSI was 7 (range 6–8), and the mean follow-up score was 0. The average decrease in the HBI was 9.5 and the average decrease in the MTLWSI was 7.


This case series indicates potential for the IBD-AID as an adjunct dietary therapy for the treatment of IBD. A randomized clinical trial is warranted.

Diet; Inflammatory bowel disease; Nutrition